Valeo Pharma Inc. News

Valeo Pharma Closes US$40 Million Non-Dilutive Financing from Sagard Healthcare Partners

Proceeds to fund acquisition of Canadian rights to 3 growing commercial stage drugs Acquisition allows Valeo to expand into Ophthalmology […]


Valeo Pharma Enters into License Agreement with Kaléo for the Canadian Rights to ALLERJECT®

700,000 Canadians suffering from severe allergies Canadian epinephrine auto-injector market exceeds $80M annually ALLERJECT peak sales potential expected to exceed $25M annually August […]


Valeo Pharma Enters into an Agreement for Ophthalmic Products, PrXIIDRA® AND PrSIMBRINZA®, in Canada

Ophthalmology becomes additional strategic therapeutic area Significant market opportunities with more than 6 million1 Canadians suffering from dry eye disease and […]


Valeo Pharma Reports Its Second Quarter 2022 Results and Highlights

Q2-22 revenues of $4.8 million, up 80% over Q2-21 Q2-22 gross margins of $1.7 million, up 134% over Q2-21 Canadian provincial public […]


Valeo Pharma to Host Second Quarter 2022 Results Conference Call / Webcast

June 8, 2022 (Source) — Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (“Valeo” or the “Company“), a Canadian pharmaceutical […]


Valeo Pharma Announces Results of Annual Meeting of Shareholders, Appointments and Options and RSU Grants

April 28, 2022 (Source) – Valeo Pharma Inc. (TSX:VPH) (OTCQB: VPHIF) (FSE:VP2) (“Valeo” or the “Company“), a Canadian pharmaceutical company, […]